Effect of MPTP on serotonergic neuronal systems and mitochondrial complex i activity in the living brain: A PET study on conscious rhesus monkeys

Journal of Nuclear Medicine

Volumn 58, Issue 7, 2017, Pages 1111-1116

  Kanazawa, Masakatsu ^a   Ohba, Hiroyuki ^a   Nishiyama, Shingo ^a   Kakiuchi, Takeharu ^a   Tsukada, Hideo ^a  

^a CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

Dopamine; Mitochondrial complex I; MPTP; Parkinson's disease; Serotonin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE 2 RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SEROTONIN 1A RECEPTOR; NEUROTOXIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN RADIOGRAPHY; CEREBELLUM; CONSCIOUSNESS; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; MALE; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RHESUS MONKEY; SEROTONINERGIC SYSTEM; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; BRAIN; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; METABOLISM; MOLECULAR IMAGING; PARKINSONISM; PROCEDURES; SEROTONINERGIC NERVE CELL; TISSUE DISTRIBUTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; DOPAMINERGIC NEURONS; ELECTRON TRANSPORT COMPLEX I; MACACA MULATTA; MALE; MOLECULAR IMAGING; NEUROTOXINS; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; SEROTONERGIC NEURONS; TISSUE DISTRIBUTION;

EID: 85021792619     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.189159     Document Type: Article

References (40)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet. 2009;373:2055-2066.
2. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839-840.
3. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med. 1988;318:876-880.
4. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 1990;54:823-827.
5. Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol. 1996;40:663-671.
6. Robinson BH. Human complex I deficiency: clinical spectrum and involvement of oxygen free radicals in the pathogenicity of the defect. Biochim Biophys Acta. 1998;1364:271-286.
7. Keeney PM, Xie J, Capaldi RA, Bennett JP Jr. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci. 2006;26:5256-5264.
8. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by MPTP. Proc Natl Acad Sci USA. 1983;80:4546-4550.
9. Tsukada H, Kanazawa M, Ohba H, Nishiyama S, Harada N, Kakiuchi T. PET imaging of mitochondrial complex I with 18F-BCPP-EF in brain of Parkinson's disease model monkey. J Nucl Med. 2016;57:950-953.
10. Brooks DJ. Imaging approaches to Parkinson disease. J Nucl Med. 2010;51:596-609.
11. Tsukada H, Ohba H, Nishiyama S, Kanazawa M, Kakiuchi T, Harada N. PET imaging of ischemia-induced impairment of mitochondrial complex I function in monkey brain. J Cereb Blood Flow Metab. 2014;34:708-714.
12. Tsukada H, Nishiyama S, Ohba H, Kanazawa M, Kakiuchi T, Harada N. Comparing amyloid-b deposition, neuroinflammation, glucose metabolism, and mitochondrial complex I activity in brain: A PET study in aged monkeys. Eur J Nucl Med Mol Imaging. 2014;41:2127-2136.
13. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5:235-245.
14. Pifl C, Schingnitz G, Hornykiewicz O. Effect of MPTP on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience. 1991;44:591-605.
15. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 1983;275:321-328.
16. Guttman M, Boileau I, Warsh J, et al. Brain serotonin transporter binding in nondepressed patients with Parkinson's disease. Eur J Neurol. 2007;14:523-528.
17. Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA. Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab. 2008;28:441-444.
18. Ballanger B, Klinger H, Eche J, et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov Disord. 2012;27:84-89.
19. Boulet S, Mounayar S, Poupard A, et al. Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis. J Neurosci. 2008;28:9575-9584.
20. Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threlkeld PG, Houle S. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of 11Clabeled 2-(phenylthio)araalkylamines. J Med Chem. 2000;43:3103-3110.
21. Le Bars D, Lemaire C, Ginovart N, et al. High-yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635. Nucl Med Biol. 1998;25:343-350.
22. Kanazawa M, Ohba H, Iwazaki A, Kakiuchi T, Tsukada H. Synthesis of 6-11Cmethyl-m-tyrosine (11C-6MemTyr) for dopamine synthesis imaging in living brain using PET. Bioorg Med Chem. 2015;23:729-734.
23. Kanazawa M, Ohba H, Harada N, Kakiuchi T, Muramatsu S, Tsukada H. Evaluation of 6-11C-methyl-m-tyrosine as a PET probe for presynaptic dopaminergic activity: A comparison PET study with b-11C-L-DOPA and 18F-FDOPA in Parkinson's disease monkeys. J Nucl Med. 2016;57:303-308.
24. Tanaka E, Kudo H. Optimal relaxation parameters of DRAMA (dynamic RAMLA) aiming at one-pass image reconstruction for 3D-PET. Phys Med Biol. 2010;55:2917-2939.
25. Jones EG, Stone JM, Karten HJ. High-resolution digital brain atlases: A Hubble telescope for the brain. Ann N Y Acad Sci. 2011;1225(suppl 1):E147-E159.
26. Logan J, Volkow ND, Fowler JS, et al. Effects of blood flow on [11C]raclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab. 1994;14:995-1010.
27. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27:1533-1539.
28. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab. 1985;5:584-590.
29. Gjedde A, Reith J, Dyve S, et al. Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci USA. 1991;88:2721-2725.
30. Eberling JL, Bankiewicz KS, O'Neil JP, Jagust WJ. PET 6-[18F]fluoro-L-mtyrosine studies of dopaminergic function in human and nonhuman primates. Front Hum Neurosci. 2008;1:9.
31. Tsukada H, Miyasato K, Kakiuchi T, Nishiyama S, Harada N, Domino EF. Comparative effects of methamphetamine and nicotine on the striatal [11C]raclopride binding in unanesthetized monkeys. Synapse. 2002;45:207-212.
32. Tsukada H, Nishiyama S, Kakiuchi T, et al. Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain. Brain Res. 1999;849:85-96.
33. Orth M, Schapira AHV. Mitochondrial involvement in Parkinson's disease. Neurochem Int. 2002;40:533-541.
34. Wu X, Kekuda R, Huang W, et al. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998;273:32776-32786.
35. Engel K, Zhou M, Wang J. Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem. 2004;279:50042-50049.
36. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24:1227-1251.
37. Hornung J-P. The human raphe system and the serotonergic system. J Chem Neuroanat. 2003;26:331-343.
38. Braak H, Del Tredici K, Rub U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.
39. Boileau I, Warsh JJ, Guttman M, et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASB. Mov Disord. 2008;23:1776-1780.
40. Politis M, Wu K, Loane C, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology. 2010;75:1920-1927.